a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05775367` - Cochlear Implants in Young Children With SSD	N/A
Completed	`NCT03875339` - Communities Helping the Hearing of Infants by Reaching Parents	N/A
Completed	`NCT01917747` - Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators	N/A
Not yet recruiting	`NCT06365749` - Genetic Feature of Congenital Hearing Loss in Chinese Population

See also

Status

Clinical Trial

Phase

Recruiting

NCT05775367 - Cochlear Implants in Young Children With SSD

N/A

Completed

NCT03875339 - Communities Helping the Hearing of Infants by Reaching Parents

N/A

Completed

NCT01917747 - Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators

N/A

Not yet recruiting

NCT06365749 - Genetic Feature of Congenital Hearing Loss in Chinese Population

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06025032
Study type	Interventional
Source	HuidaGene Therapeutics Co., Ltd.
Contact	Study Director
Phone	+86 021-25076143
Email	HG20501@huidagene.com
Status	Not yet recruiting
Phase	Early Phase 1
Start date	November 30, 2024
Completion date	April 28, 2030

a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms